Onkologie. 2008:2(1):33-37

Did the introduction of targeted therapy limit the importance of cytostatic treatment?

Pavel Klener
1. interní klinika 1. LF a ÚHKT, Praha

Anticancer chemotherapy is one of the basic methods for cancer treatment. However, its mechanism of action is not specific, and therefore it may cause a damage on a normal cells and tissues. On the other hand, in recent years, many specific inhibitors of cancerogenesis has been discovered. This so called targeted therapy significantly improved therapeutic otcome. The most promissing seems to be inhibitors of proteinkinases and monoclonal antibodies. This review gives a detailed information of a broad spectrum of monoclonal antibodies, and compare its impact on the treatment of different malignancies. There is also mentioned the role of newly introduced cytotoxic drugs and their role for combination with targeted therapy. Altough the targeted therapy is an effective contribution to the treatment results in oncology, it could in any case replaced the conventional chemotherapy.

Keywords: anticancer chemotherapy, targeted therapy, monoclonal antibodies, new cytotoxic drugs

Published: April 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Klener P. Did the introduction of targeted therapy limit the importance of cytostatic treatment? Onkologie. 2008;2(1):33-37.
Download citation

References

  1. Aksoy S, Harpuoglu H, Kilickap S et al. Rituximab-related viral infections in lymphoma patients. Leuk. Lymphoma 2007; 48: 1307-1312. Go to original source... Go to PubMed...
  2. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp. Clin. Pharmacol. 2007; 29: 231-245. Go to PubMed...
  3. Czuczman MS, Thall A, Witzig TE et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J. Clin. Oncol. 2005; 23: 4390-4398. Go to original source... Go to PubMed...
  4. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin´s lymphoma. Drugs 2007; 67: 333-350. Go to original source... Go to PubMed...
  5. Feldman EJ, Brandwein J, Stone R et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, Lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory ir first relapsed acute myeloid leukemia. J. Clin. Oncol. 2005; 23: 4110-4116. Go to original source... Go to PubMed...
  6. Fing-Bennett DM, Thomas K. 90Y-ibritumomab tiuxetan in the treatment of relapsed of refractory B-cell non Hodgkin´s lymphoma. J. Nucl. Med. Technol. 2003; 31: 61-68.
  7. Ghoshal K, Bai S. DNA methyltransferases as targets for cancer therapy. Drugs today (Barc.); 43: 395-422. Go to PubMed...
  8. Hajdůch M, Michálek J, Papajík T et al. Monoklonální protilátky v onkologii, Praha: Mediforum, 2000.
  9. Kim Y, Duvic E, Obitz E et al. Clinical efficacy of zanolimumab (HuMax-CD-4): Two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood, 2007; 109: 4655-4662. Go to original source... Go to PubMed...
  10. Klener P. Klinická onkologie. Praha: Galén Karolinum, 2002.
  11. Klener P. Bevacizumabum. Remedia 2005; 15: 312-315. Go to original source...
  12. Klener P. Cílená terapie v onkologii. Postgrad. Med. 2007; 9: 128-134.
  13. Labianca R, La Verde N, Garassimo MC. Development and clinical indication of cetuximab. Intj. Biol. Markers 2007; 22 (Suppl 4): 40-46. Go to original source... Go to PubMed...
  14. Messersmith WA, Hidalgo M. Panitumomab, a monoclonal antiepidermal growth factor receptor antibody in colorectal cancer: another one or one? Clin. Cancer Res 2007; 13: 4664-4666. Go to original source... Go to PubMed...
  15. Nishimoto N, Sasi M, Shima Y et al. Improvement in Castelman´s disease by humanized antiinterleukin 6 receptor antibody therapy. Blood 2000; 95: 56-61. Go to original source...
  16. Sharkey RM, Goldenberg DM. Targeted therapy of cancer: New prospects for antibodies and immunoconjugates- CA Cancer J. Clin. 2006; 56: 226-243. Go to original source... Go to PubMed...
  17. Skálová A, Vaněček T, Losan F et al. Detekce HER. 2/neu u karcinomu prsu. Čas. lék. čes. 2003; 142: 93-98.
  18. Tabernero TE, Fornierr M, Conté P et al. Phase II clinical trial of ixabepilon (BMS-247550), en epothilone analogue in patients with taxane-resistent metastatic breast cancer. J. Clin. Oncol. 2007; 25: 3399-3406. Go to original source... Go to PubMed...
  19. Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004; 104: 1793-1800. Go to original source... Go to PubMed...
  20. Trněný M, Klener P. Deset let od úspěšného zavedení prvé monoklonální protilátky (rituximabu) do léčby lymfomů. Čas. lék. čes. 2007; 146: 578-585.
  21. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541-5552. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.